Treatment with Vyvgart (efgartigimod alfa-fcab) helped reduce the impact of generalized myasthenia gravis (gMG) on activities of daily living among adults who tested negative for antibodies targeting the acetylcholine receptor (AChR) […] The post Vyvgart eases gMG impact on daily living in seronegative adults in trial appeared first on Myasthenia Gravis News.| Myasthenia Gravis News – The Web's Daily Resource for Myasthenia Gravis News
Into-the-vein treatment with Vyvgart (efgartigimod alfa) resolved an MG crisis in a man who had failed to respond to prior treatments.| Myasthenia Gravis News